Form 4: BDX Executive Sells Shares Under 10b5-1 Plan

Becton Dickinson & Co. EVP Michael Feld reported a planned sale of 75 common shares at $193.36 per share, executed under a Rule 10b5-1 plan.

Summary

• Michael Feld, EVP, CRO & President of Life Sciences at Becton Dickinson & Co. (BDX), reported a sale of common stock.
• The transaction involved the disposition of 75 shares of common stock.
• The shares were sold at a price of $193.36 per share.
• Following this transaction, Michael Feld beneficially owns 16,580 shares of common stock directly.
• The sale was executed on December 1, 2025, and was made pursuant to a Rule 10b5-1 plan adopted on February 7, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a routine, pre-planned insider sale of a small number of shares, which does not indicate a significant change in company outlook or executive confidence.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 plan, indicating a planned and non-discretionary sale, which can mitigate concerns about opportunistic insider selling.

Negatives

• An insider sale, even if planned, can sometimes be perceived negatively by investors, though the small volume in this instance limits its significance.

Future Outlook

There are no forward-looking statements or guidance provided in this filing.

Industry Context

This is an individual executive's stock transaction and does not directly relate to broader industry trends or competitors, beyond being a routine insider filing for a major medical technology company.

Stakeholder Impact

• Shareholders: Minimal impact due to the small volume of shares sold. The 10b5-1 plan indicates a pre-planned, non-discretionary sale.

Key Dates

Recommendation

The filing details a routine, pre-planned insider sale of a very small number of shares by an executive. This type of transaction, especially when executed under a 10b5-1 plan, typically does not signal a change in the company's fundamental prospects or the executive's long-term confidence. Therefore, it provides no new information that would warrant a change in investment recommendation for BDX.

Keywords

Becton Dickinson, BDX, Michael Feld, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation